Global Kidney Cancer Drugs Market Report 2021: COVID-19


New York, June 22, 2021 (GLOBE NEWSWIRE) – announces the publication of the report “Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030” – / p06097027 /? utm_source = GNW
$ 3 billion in 2020 to $ 3.29 billion in 2021 at a compound annual growth rate (CAGR) of -0.3%. The slow decline is mainly due to the COVID-19 epidemic which has caused the postponement of immunocompromised treatments. The market is expected to reach $ 3.6 billion in 2025 at a CAGR of 2.3%.

The kidney cancer drugs market includes sales of kidney cancer drugs. It includes immunotherapy, chemotherapy and targeted therapy

The market covered in this report is segmented by Type into Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) or Urothelial Cell Carcinoma (UCC); by product in nexavar (sorafenib), sutent (sunitinib), Afinitor (everolimus), votrient (pazopanib), avastin (bevacizumab), inlyta (axitinib), torisel (temsirolimus), proleukin (aldesleukin), others; by end users in hospitals, clinics, research centers, others.

The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East & Africa.

The increasing use of biologics and targeted therapies is acting as a drag on the kidney cancer drug market. When kidney cancer spreads to other organs, targeted therapies are used to control kidney cancer when chemical drugs are ineffective.

In addition, targeted drugs are used after kidney cancer surgery to prevent kidney cancer from coming back. Conventional chemical drugs cannot be used in the same way.

In addition, targeted therapies for kidney cancer have been shown to be more effective than normal drug-based chemical chemotherapy in randomized clinical trials. In a study conducted by Pfizer, the use of targeted therapy was more likely to shrink the tumor than the use of chemical drugs.

The targeted drug, axitinib and pembrolizumab, are used to treat stage IV kidney cancer, which especially attacks where the cancer has spread. Thus, the pharmaceutical industry adopts the targeted therapies due to the advantages mentioned above. Hence, hampering the growth of the kidney cancer drugs market.

The use of combination therapy is all the rage in the kidney (renal) cancer drug market. Combination therapy combines the effects of various drugs, thereby reducing the likelihood that cancer-resistant cells will develop.

Better understanding of the causes and effects of kidney cancer led to the discovery of combination therapy. As part of this treatment, vascular endothelial growth factor (VEGF) drugs, which stimulate the protein in the blood, are combined with inhibitors of the mammalian target of rapamycin (mTor), which helps promote biogenesis. cellular.

According to a study conducted by the National Cancer Institute (NIH) in 2019, the combination treatment leads to better results in patients with advanced kidney cancer. In April 2019, Merck obtained approval from the Food and Drug Administration (FDA) to combine their drug Pembrolizumab, which strengthens patients’ immune systems with Pfizer’s drug Axitinib, which prevents the spread of kidney cancer, this combination medication can help increase the rate of recovery in patients with advanced kidney cancer.

In April 2019, Bristol-Myers Squibb Company, a US pharmaceutical company was granted approval to acquire Celgene Corporation for $ 74 billion. The transaction is expected to create a leading specialty company that would serve the needs of patients with cancer, inflammatory and immunological diseases and cardiovascular diseases through innovative high-value drugs and cutting-edge scientific capabilities.

Celgene corporation, a company that develops drugs for cancer and inflammatory disorders, was founded in 1996 and is headquartered in the United States.

One of the major drivers of the kidney cancer drug market is the increase in the incidence of kidney cancer. People’s lifestyle change, tobacco consumption and poor diet are some of the factors that contribute to the growth of these kidney cancer cells.

According to the American Cancer Society report, an estimated 73,750 new cases of kidney (renal) cancer were diagnosed in the United States in 2020. This has led to the growth of the kidney cancer drug market.

The kidney cancer drug market is governed by the regulatory framework of agencies such as the Food and Administration Agency (FDA) and the American Society of Clinical Oncology (ASCO). The FDA recommendations for the kidney cancer drug industry in the form of guidelines are mentioned in the CFR. (Code for Federal Regulations) title number 21 under part 312, which contains subparts from subpart “A” to subpart “I”.

Subpart “E” deals with procedures designed to aid in the development, evaluation and commercialization of drugs related to therapies aimed at treating people with life-threatening diseases such as kidney cancer. Subpart “E” also includes guidelines for monitoring and evaluating clinical trials of kidney cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments.

All companies operating in the kidney cancer drug industry are required to comply with FDA regulations.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, United Kingdom and United States.

Read the full report:

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.



About Hector Hedgepeth

Check Also

China, not Europe, is keeping policymakers in Washington awake at night

Last week was good for Western democracies. In the midterm elections in the United States, …

Leave a Reply

Your email address will not be published.